Sanofi signed a deal with Earendil Labs for $125 million upfront and $1.72 billion in milestone payments. Regeneron ...

Regeneron Pharmaceuticals (REGN) and Sanofi (SNY) announced that the U.S ... U.S. with inadequately controlled disease on standard-of-care treatment who, until now, had limited treatment options ...

Regeneron (REGN) and Sanofi (SNY) announced that the Ministry of Health, Labour and Welfare in ... added to background maximal standard-of-care inhaled therapy in adults with uncontrolled COPD ...

Dupixent, which was rejected by the FDA for chronic spontaneous urticaria in October 2023, is now approved as the first new targeted therapy for the indication in more than 10 years.

Sanofi SNY and Regeneron REGN announced encouraging data ... six years and older who remained symptomatic despite standard-of-care (SOC) antihistamines and were not previously treated with ...

April 18 (Reuters) - The U.S. Food and Drug Administration approved the use of Sanofi (SASY.PA), opens new tab and Regeneron's ... 5:44 AM UTC · Updated ago Healthcare & Pharmaceuticalscategory ...

Sanofi and Regeneron acknowledged that testing their inflammatory disease blockbuster Dupixent in chronic obstructive pulmonary disease (COPD) was likely to be high-risk when they launched phase 3 ...

If Sanofi opts in to the other project, Regeneron will lead MUC16xCD3 bispecific development and marketing in the US. The companies will share development costs and profits.